Veyonda and Radiotherapy Delivers Clinical Benefits
Filed with ASX · · 5 pages · English
Earlier from Noxopharm
- Principal Investigator Discusses LuPIN-1 Study
- NOX Receives $3.26M Federal Govt R&D Rebate
- DARRT-1 study advancing on basis of positive clinical data
- NOX announces Positive Data from CEP-1 Study of Veyonda
- NOX to Present Clinical Data at COSA Annual Meeting
Later from Noxopharm
- FNN interview with Nox Chief Medical Officer on Interim Data
- Noxopharm to expedite Veyonda Clinical Program
- KZA: Kazia sells stake in Noxopharm
- Veyonda Chemotherapy Enhancement Program to be Expanded
- Idronoxil Confirmed as New Immuno-Oncology Drug
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm